Contineum Therapeutics (CTNM) Competitors

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.

Is AMLX or CTNM more profitable?

Amylyx Pharmaceuticals' return on equity of -36.97% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-36.97%	-29.61%
Contineum Therapeutics	N/A	-49.92%	-20.52%

Which has preferable valuation & earnings, AMLX or CTNM?

Amylyx Pharmaceuticals has higher earnings, but lower revenue than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	-$1.27M	-391.04	$49.27M	-$3.11	-1.79
Contineum Therapeutics	$50M	2.40	$22.72M	-$1.97	-2.35

Which has more risk and volatility, AMLX or CTNM?

Amylyx Pharmaceuticals has a beta of -0.59, indicating that its stock price is 159% less volatile than the S&P 500. Comparatively, Contineum Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.

Does the MarketBeat Community prefer AMLX or CTNM?

Amylyx Pharmaceuticals received 27 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 70.18% of users gave Amylyx Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Amylyx Pharmaceuticals	Outperform Votes 40 70.18%	Underperform Votes 17 29.82%
Contineum Therapeutics	Outperform Votes 13 100.00%	Underperform Votes No Votes

Do analysts prefer AMLX or CTNM?

Amylyx Pharmaceuticals presently has a consensus price target of $9.83, indicating a potential upside of 76.22%. Contineum Therapeutics has a consensus price target of $22.50, indicating a potential upside of 385.96%. Given Contineum Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Contineum Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.11
Contineum Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20

Does the media prefer AMLX or CTNM?

In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than Contineum Therapeutics. MarketBeat recorded 5 mentions for Amylyx Pharmaceuticals and 1 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.89 beat Amylyx Pharmaceuticals' score of 0.48 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Amylyx Pharmaceuticals	Neutral
Contineum Therapeutics	Very Positive

Do insiders and institutionals hold more shares of AMLX or CTNM?

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 11.3% of Contineum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Amylyx Pharmaceuticals and Contineum Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.